Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
NCT05730010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 289
Last updated 2023-08-03
Summary
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
Conditions
Sponsors & Collaborators
-
Indiana University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-16
- Primary Completion
- 2023-06-26
- Completion
- 2023-06-26
Countries
- United States
Study Locations
More Related Trials
-
Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients
NCT03881384 ·Status: UNKNOWN
-
Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT03260192 ·Status: RECRUITING
-
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
NCT05427617 ·Status: COMPLETED
-
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
NCT02743910 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Application of ctDNA in Early Screening of Breast Cancer
NCT03973034 ·Status: UNKNOWN
-
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531 ·Status: RECRUITING ·Phase: PHASE2
-
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
NCT03688035 ·Status: UNKNOWN
-
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
NCT05058183 ·Status: RECRUITING ·Phase: NA
-
Study on Early Auxiliary Diagnosis and Postoperative Recurrence Monitoring of Breast Cancer
NCT05858242 ·Status: RECRUITING
-
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
NCT03511859 ·Status: UNKNOWN
-
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
NCT06706557 ·Status: RECRUITING
-
Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer
NCT05945290 ·Status: COMPLETED
-
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
NCT06479460 ·Status: RECRUITING
-
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
NCT05333874 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT05914792 ·Status: ACTIVE_NOT_RECRUITING
-
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
NCT07332975 ·Status: RECRUITING
-
Clinical Application of CTDNA in Operable Breast Cancer Patients
NCT02797652 ·Status: UNKNOWN
-
Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
NCT06876610 ·Status: RECRUITING
-
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy
NCT00897299 ·Status: COMPLETED
-
Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing
NCT01992471 ·Status: COMPLETED
-
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NCT07025785 ·Status: RECRUITING ·Phase: NA
-
A Study to Identify Breast Cancer (IDBC)
NCT04495244 ·Status: UNKNOWN
-
Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer
NCT07136493 ·Status: SUSPENDED ·Phase: NA
-
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
NCT06698679 ·Status: RECRUITING
-
Genetic Studies in Breast Cancer
NCT00582322 ·Status: COMPLETED